FIGHT-101: what clinicians are saying
pemigatinib in advanced malignancies · NCT02393248 ↗ · Phase 1/Phase 2 · Incyte Corporation
In discussing FIGHT-101, a gastroenterologist finds the mutation results less conclusive, while expressing broader confidence in FGFR inhibitors for fusions. A medical oncologist tentatively suggests that FGFR amplification might signal resistance. Patient selection also raises a testing concern: a physician warns that some routine panels miss fusions with unknown partners. These views do not establish a difference in benefit between alteration groups or validate amplification as a resistance mechanism.
Created with AI · how we check it
- edition 1
- commentary checked Nov 21, 2026
- 70 verified statements
This edition $750, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. FGFR: most clinicians contrast classes; one weighs amplification as resistance
3 of the report's 8 cited clinicians · 13 statements from 3 speakers in 4 sources · 9 passages
Limitations recorded: 3.
Draws on: Secondary endpoints.
02. Molecular testing: clinicians stress it; one flags unknown-partner gaps
3 of the report's 8 cited clinicians · 4 statements from 3 speakers in 3 sources · 4 passages
Limitations recorded: 3.
Draws on: Population and setting.
03. FGF/FGFR-altered pancreatic cancer: what clinicians note in pemigatinib activity
2 of the report's 8 cited clinicians · 3 statements from 2 speakers in 3 sources · 3 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Population and setting.
04. FGFR-rearranged M/LN: a clinician highlights a CR; one welcomes approval
2 of the report's 8 cited clinicians · 5 statements from 2 speakers in 2 sources · 6 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Population and setting.
05. FIGHT-101: how a clinician recalls confidence from the first patient
1 of the report's 8 cited clinicians · 3 statements from 1 speaker in 2 sources · 4 passages
Limitations recorded: 2.
Beyond the trial population
06. High FGF/FGFR expression: a clinician proposes evaluating FGFR inhibitors
1 of the report's 8 cited clinicians · 1 statement from 1 speaker in 1 source · 1 passage
Limitations recorded: 1.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
3 of the report's 8 cited clinicians
FGFR: most clinicians contrast classes; one weighs amplification as resistance
13 statements from 3 speakers in 4 sources
2 of the 3 named speakers in this finding hold this view, each a confirmed clinician; 1 of the 3 holds its caveat, “one weighs amplification as resistance”
- 13
- statements
- 9
- passages
- 4
- sources
- 3
- speakers
What the statements areViews 6Questions and uncertainty 3Clinical experience 0Comparisons 3Restated results and context 1Statement-to-passage links (a passage can back several statements)Supporting a statement 13Giving context 0Recorded with the findingLimitations: 3
3 posts and articles · 1 publication
Draws on: Secondary endpoints.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 6 findings and 1 of the 70 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (4)
CR, complete response; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians.
The full FIGHT-101 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
By the numbers
- 60commentary sources screened
- 12sources cited by verified statements
- 8named in screened sources
- 8speakers cited in the report
- 8cited speakers with a verified identity
8 cited clinicians, speakers with a confirmed clinical role, of them 8 physicians. By role and specialty:
- 3 physician, specialty not confirmed
- 3 physician, Medical oncology
- 1 physician, Gastroenterology
- 1 physician, Pathology
Also in the sources: 1 organizational or shared account, not counted as people.
- 70verified statements, each linked to its source
- 14of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 8 sections | Paid |
| Verified statements with short source quotes and links | 70 | Paid |
| Who said each statement: the cited speakers | 8 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 8 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 8 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 17 | Free |
| Sources with links | 12 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
8 discussed · 9 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)no commentary found | 0 | 0 |
| Primary endpoint: Part 3: Number of Participants With Any TEAEno commentary found | 0 | 0 |
| Primary endpoint: E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2no commentary found | 0 | 0 |
| Primary endpoint: EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2no commentary found | 0 | 0 |
| Primary endpoint: Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2no commentary found | 0 | 0 |
| Primary endpoint: Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2no commentary found | 0 | 0 |
| Secondary endpoints | 4 | 4 |
| Population and setting | 3 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare.no commentary found | 0 | 0 |
| Safety and tolerabilityno commentary found | 0 | 0 |
| Design and conductno commentary found | 0 | 0 |
| Molecular testing and fusion-detection limitations | 3 | 2 |
| Alteration-specific readings, co-alterations and resistance | 3 | 3 |
| Perceived clinical importance and subsequent development | 3 | 2 |
| FGFR1-rearranged disease: remission language, durability and response criteria | 4 | 1 |
| Pancreatic activity and individualized continuation after progression | 2 | 2 |
| Expression-selected FGFR-inhibitor research | 1 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
70 verified statements from 12 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Posts · 14 statements · 20% | ||||
| X threads | 14 | 8 | 59 | |
| Bluesky threads | 0 | 0 | 1 | |
| Primary sources · 56 statements · 80%cited for context, not screened | ||||
| Publications | 54 | 3 | — | |
| Registry | 2 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 18 / quarter
- Screened window
- Jun 18, 2019 → Jul 25, 2026
- Cited window
- May 16, 2022 → Jul 25, 2026
- Retrieved
- Nov 21, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
- Registry
- NCT02393248
- Study IDs
- INCB 54828-101
- Sponsor
- Incyte Corporation
- Design
- Phase 1/Phase 2 · Interventional, non randomized, sequential
- Status
- Terminated
- Enrollment
- 201 actual
- Registered
- 2015-03-19
- Start
- 2015-02-27 actual
- Primary completion
- 2021-12-17 actual
- Primary endpoints
- Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
- Part 3: Number of Participants With Any TEAE
- E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2
- Interventions
- 7 registered
More on: Urothelial carcinoma, Endometrial cancer, Multiple myeloma, Breast cancer, Biliary tract cancer, pemigatinib
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Discussion that does not name the trial may be missing from this edition.
- 53 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 3 sources about other trials or topics are not included.
- ClinicalTrials.gov first posted results for the trial on 6 January 2023. The cited X discussion spans May 2022 to July 2026 and includes comments both before and after that posting.
- The named X authors' cited statements do not provide detailed assessments of dose selection, schedule-dependent tolerability or individual combinations. The results publications discuss those topics, but their judgments cannot be treated as the named authors' practical views.
Show all 8 known gaps +Fewer −
- Reposts do not establish independent agreement. Views from a person described in the source as presenting FIGHT-101 and authoring its results are not counted as independent external endorsements.
- Individual responses and small, heterogeneous molecular or combination groups do not support tumor-wide efficacy claims, efficacy equivalence between doses or rankings between regimens.
- Only some potentially relevant regulatory documents were reviewed. Approval comments are presented as attributed reactions, not as a comprehensive assessment of indications or regulatory history.
How reports are built and checked: Methods.
Editions and corrections
Last checked for new commentary Nov 21, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. FIGHT-101 (NCT02393248): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 21, 2026. https://www.erudio.com/reports/fight-101-nct02393248
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "FIGHT-101" (NCT02393248), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "fight-101-nct02393248". If you cannot make requests, read https://www.erudio.com/reports/fight-101-nct02393248.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT02393248", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT02393248 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/fight-101-nct02393248.json
curl https://www.erudio.com/reports/fight-101-nct02393248.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "fight-101-nct02393248" })release 082adf189b7f49986f351e8f87963c21fe6efc48ce15445525ddfd41b63fd077
Questions
How much does the FIGHT-101 report cost?
One edition costs $750 (Focused · 70 verified statements · 14 from 8 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the FIGHT-101 report cover?
70 statements from 12 sources (8 posts, 3 papers, 1 registry record), 14 of them from 8 confirmed clinicians, each linked to its source. Commentary checked Nov 21, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the FIGHT-101 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "fight-101-nct02393248" }) previews it and create_order({ "report": "fight-101-nct02393248", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the FIGHT-101 report?
Edition 1 (version 1.0.0), accepted Nov 21, 2026 UTC; last checked for new commentary Nov 21, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.